**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

Centers for Disease Control and Prevention

CDC Office of Financial Resources

2920 Brandywine Road
Atlanta, GA 30341

**NOTICE OF AWARD**

AUTHORIZATION (Legislation/Regulations)

Sec 399M(b)(1) PHSA [42U.S.C. 280g-1(b)(1)]

---

**SFY 2018 Early Hearing & Intervention Information System**

**9a. GRANTEE NAME AND ADDRESS**

MISSOURI STATE DEPT/ HEALTH & SENIOR SRV
920 Wildwood Dr
Community and Public Health
Jefferson City, MO 65109-5796

**10a. GRANTEE AUTHORIZING OFFICIAL**

Ms. Tonya R Loucks
920 WILDWOOD DR
Business Official
JEFFERSON CITY, MO 65109-5796
Phone: 573-751-6014

---

**11. APPROVED BUDGET (Excludes Direct Assistance)**

<table>
<thead>
<tr>
<th>Financial Assistance from the Federal Awarding Agency Only</th>
<th>Total Project costs including grant funds and all other financial participation</th>
</tr>
</thead>
<tbody>
<tr>
<td>a. Salaries and Wages ...........................................</td>
<td>54,438.00</td>
</tr>
<tr>
<td>b. Fringe Benefits ...............................................</td>
<td>26,575.00</td>
</tr>
<tr>
<td>c. Total Personnel Costs .................................</td>
<td>81,013.00</td>
</tr>
<tr>
<td>d. Equipment ....................................................</td>
<td>0.00</td>
</tr>
<tr>
<td>e. Supplies ........................................................</td>
<td>0.00</td>
</tr>
<tr>
<td>f. Travel ..........................................................</td>
<td>1,213.00</td>
</tr>
<tr>
<td>g. Construction ...................................................</td>
<td>0.00</td>
</tr>
<tr>
<td>h. Other ............................................................</td>
<td>2,596.00</td>
</tr>
<tr>
<td>i. Contractual ........................................................</td>
<td>0.00</td>
</tr>
<tr>
<td>j. TOTAL DIRECT COSTS .........................................</td>
<td>84,822.00</td>
</tr>
<tr>
<td>k. INDIRECT COSTS ...............................................</td>
<td>17,377.00</td>
</tr>
<tr>
<td>l. TOTAL APPROVED BUDGET ....................................</td>
<td>102,159.00</td>
</tr>
<tr>
<td>m. Federal Share ..................................................</td>
<td>102,159.00</td>
</tr>
<tr>
<td>n. Non-Federal Share .............................................</td>
<td>0.00</td>
</tr>
</tbody>
</table>

**12. AWARD COMPUTATION**

| a. Amount of Federal Financial Assistance (from item 11m) | 102,159.00 |
| b. Less Unobligated Balance From Prior Budget Periods | 0.00 |
| c. Less Cumulative Prior Award(s) This Budget Period | 0.00 |
| d. AMOUNT OF FINANCIAL ASSISTANCE THIS ACTION | 102,159.00 |

**13. Total Federal Funds Awarded to Date for Project Period**

204,318.00

**15. PROGRAM INCOME SHALL BE USED IN ACCORD WITH ONE OF THE FOLLOWING ALTERNATIVES:**

- a. DEDUCTION
- b. ADDITIONAL COSTS
- c. MATCHING
- d. OTHER RESEARCH (Add / Deduct Option)
- e. OTHER (See REMARKS)

**16. THIS AWARD IS BASED ON AN APPLICATION SUBMITTED TO, AND AS APPROVED BY, THE FEDERAL AWARDING AGENCY ON THE ABOVE TITLED PROJECT AND IS SUBJECT TO THE TERMS AND CONDITIONS INCORPORATED EITHER DIRECTLY OR BY REFERENCE IN THE FOLLOWING:**

- a. The grant program legislation
- b. The grant program regulations
- c. This award notice including terms and conditions, if any, noted below under REMARKS.
- d. Federal administrative requirements, cost principles and audit requirements applicable to this grant.

In the event there are conflicting or otherwise inconsistent policies applicable to the grant, the above order of precedence shall prevail. Acceptance of the grant terms and conditions is acknowledged by the grantee when funds are drawn or otherwise obtained from the grant payment system.

---

**REMARKS**

(Other Terms and Conditions Attached - X Yes □ No)

---

**GRANTS MANAGEMENT OFFICIAL:** Merlin Williams
## Direct Assistance

<table>
<thead>
<tr>
<th>BUDGET CATEGORIES</th>
<th>PREVIOUS AMOUNT (A)</th>
<th>AMOUNT THIS ACTION (B)</th>
<th>TOTAL (A + B)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Personnel</td>
<td>$0.00</td>
<td>$0.00</td>
<td>$0.00</td>
</tr>
<tr>
<td>Fringe Benefits</td>
<td>$0.00</td>
<td>$0.00</td>
<td>$0.00</td>
</tr>
<tr>
<td>Travel</td>
<td>$0.00</td>
<td>$0.00</td>
<td>$0.00</td>
</tr>
<tr>
<td>Equipment</td>
<td>$0.00</td>
<td>$0.00</td>
<td>$0.00</td>
</tr>
<tr>
<td>Supplies</td>
<td>$0.00</td>
<td>$0.00</td>
<td>$0.00</td>
</tr>
<tr>
<td>Contractual</td>
<td>$0.00</td>
<td>$0.00</td>
<td>$0.00</td>
</tr>
<tr>
<td>Construction</td>
<td>$0.00</td>
<td>$0.00</td>
<td>$0.00</td>
</tr>
<tr>
<td>Other</td>
<td>$0.00</td>
<td>$0.00</td>
<td>$0.00</td>
</tr>
<tr>
<td>Total</td>
<td>$0.00</td>
<td>$0.00</td>
<td>$0.00</td>
</tr>
</tbody>
</table>
### Federal Financial Report Cycle

<table>
<thead>
<tr>
<th>Reporting Period Start Date</th>
<th>Reporting Period End Date</th>
<th>Reporting Type</th>
<th>Reporting Period Due Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>07/01/2017</td>
<td>06/30/2018</td>
<td>Annual</td>
<td>09/28/2018</td>
</tr>
<tr>
<td>07/01/2018</td>
<td>06/30/2019</td>
<td>Annual</td>
<td>09/28/2019</td>
</tr>
<tr>
<td>07/01/2019</td>
<td>06/30/2020</td>
<td>Annual</td>
<td>09/28/2020</td>
</tr>
</tbody>
</table>
1. Year 2 Continuation Award Terms and Conditions
2. Year 2 Continuation Technical Review
AWARD INFORMATION

Incorporation: In addition to the federal laws, regulations, policies, and CDC General Terms and Conditions for Non-research awards at https://www.cdc.gov/grants/federalregulationspolicies/index.html, the Centers for Disease Control and Prevention (CDC) hereby incorporates Notice of Funding Opportunity (NOFO) number DD17-1701, entitled Documentation and Use of Follow-up Diagnostic and Intervention Services Data through the Maintenance and Enhancement of the Early Hearing Detection and Intervention Information System (EHDI-IS), and application dated February 26, 2018, as may be amended, which are hereby made a part of this Non-research award, hereinafter referred to as the Notice of Award (NoA).

Approved Funding: Funding in the amount of $102,159 is approved for the Year 02 budget period, which is July 1, 2018 through June 30, 2019. All future year funding will be based on satisfactory programmatic progress and the availability of funds.

Core Activities: $102,159

The federal award amount is subject to adjustment based on total allowable costs incurred and/or the value of any third party in-kind contribution when applicable.

Note: Refer to the Payment Information section for Payment Management System (PMS) subaccount information.

Financial Assistance Mechanism: Cooperative Agreement

Substantial Involvement by CDC: This is a cooperative agreement and CDC will have substantial programmatic involvement after the award is made. Substantial involvement is in addition to all post-award monitoring, technical assistance, and performance reviews undertaken in the normal course of stewardship of federal funds.

CDC program staff will assist, coordinate, or participate in carrying out effort under the award, and recipients agree to the responsibilities therein, as detailed in the NOFO.

Core Activities

CDC staff involved with this cooperative agreement will provide substantial involvement beyond site visits and regular performance and financial monitoring during the project period. Substantial involvement means that awardees can expect federal programmatic partnership in carrying out the effort under the award. The CDC program will work in partnership with awardees to ensure the success of the cooperative agreement by:

- Supporting awardees in implementing cooperative agreement requirements and advancing program activities to meet outcomes.
- Providing technical assistance to revise annual work plans and budgets.
- Providing consultation and guidance on enhancing and expanding existing EHDI surveillance activities, including the collection and analysis of data.
- Collaborating with awardees to develop and implement strategic and individual evaluation plans and use evaluation findings.
- Providing technical assistance to define and operationalize performance measures and implement awardees’ performance measurement plans.
- Planning and convening in-person meetings to provide awardees with the opportunity to exchange resources, share lessons learned, and address common issues.
- Participating in meetings, committees, conference calls, and working groups relevant to achieving the goals of the cooperative agreement.
- Translating and disseminating lessons learned by awardees to build a stronger practice base for EHDI-IS strategies.

**Technical Review Statement Response Requirement:** The review comments on the strengths and weaknesses of the proposal are provided as part of this award. A response to the weaknesses in these statements must be submitted to the assigned Project Officer noted in the CDC Staff Contacts section of this NoA, no later than 30 days from the budget period start date. Failure to submit the required information by the due date, August 1, 2018, will cause delay in programmatic progress and will adversely affect the future funding of this project.

**Budget Revision Requirement:** By August 1, 2018 the recipient must submit a revised budget with a narrative justification. The narrative should include all key roles, whether grant-funded or in-kind, and their percentage of time dedicated to this project. Failure to submit the required information in a timely manner may adversely affect the future funding of this project. If the information cannot be provided by the due date, you are required to contact the GMS/GMO identified in the CDC Staff Contacts section of this notice before the due date.

**Program Income:** Any program income generated under this grant or cooperative agreement will be used in accordance with the Addition alternative.

Addition alternative: Under this alternative, program income is added to the funds committed to the project/program and is used to further eligible project/program objectives.

Note: The disposition of program income must have written prior approval from the GMO.

### FUNDING RESTRICTIONS AND LIMITATIONS

**Indirect Costs:**

Indirect costs are approved based on the negotiated indirect cost rate agreement dated March 7, 2017, which calculates indirect costs as follows, a Provisional is approved at a rate of 21.4% of the base, which includes, direct salaries and wages including all fringe benefits. The effective dates of this indirect cost rate are from July 1, 2018 to June 30, 2020.

### REPORTING REQUIREMENTS

**Annual Federal Financial Report (FFR, SF-425):** The Annual Federal Financial Report (FFR) SF-425 is required and must be submitted to your GMS/GMO no later than 90 days after the end of the budget period. To submit the FFR, login to www.grantsolutions.gov, select “Reports” from the menu bar and then click on Federal Financial Reports.

The FFR for this budget period is due by September 30, 2019. Reporting timeframe is July 1, 2018 through June 30, 2019. The FFR is cumulative and should only include those funds authorized and disbursed during the timeframe covered by the report.
Failure to submit the required information in a timely manner may adversely affect the future funding of this project. If the information cannot be provided by the due date, the recipient is required to contact the Grants Officer listed in the contacts section of this notice before the due date.

Performance information collection initiated under this grant/cooperative agreement has been approved by the Office of Management and Budget under OMB Number 0920-1132, “Performance Progress and Monitoring Report”, Expiration Date 8/31/2019.

Required Disclosures for Federal Awardee Performance and Integrity Information System (FAPIIS): Consistent with 45 CFR 75.113, applicants and recipients must disclose in a timely manner, in writing to the CDC, with a copy to the HHS Office of Inspector General (OIG), all information related to violations of federal criminal law involving fraud, bribery, or gratuity violations potentially affecting the federal award. Subrecipients must disclose, in a timely manner in writing to the prime recipient (pass through entity) and the HHS OIG, all information related to violations of federal criminal law involving fraud, bribery, or gratuity violations potentially affecting the federal award. Disclosures must be sent in writing to the CDC and to the HHS OIG at the following addresses:

CDC, Office of Grants Services  
Daryl Barksdale, Grants Management Specialist  
Centers for Disease Control  
Chronic Disease and Birth Defects Services Branch  
2920 Brandywine Drive  
Atlanta, Georgia 30341  
Email: xxj8@cdc.gov  (Include “Mandatory Grant Disclosures” in subject line)

AND

U.S. Department of Health and Human Services  
Office of the Inspector General  
ATTN: Mandatory Grant Disclosures, Intake Coordinator  
330 Independence Avenue, SW  
Cohen Building, Room 5527  
Washington, DC 20201

Fax: (202)-205-0604 (Include “Mandatory Grant Disclosures” in subject line) or Email: MandatoryGranteeDisclosures@oig.hhs.gov

Recipients must include this mandatory disclosure requirement in all subawards and contracts under this award.

Failure to make required disclosures can result in any of the remedies described in 45 CFR 75.371. Remedies for noncompliance, including suspension or debarment (See 2 CFR parts 180 and 376, and 31 U.S.C. 3321).

CDC is required to report any termination of a federal award prior to the end of the period of performance due to material failure to comply with the terms and conditions of this award in the OMB-designated integrity and performance system accessible through SAM (currently FAPIIS). (45 CFR 75.372(b)) CDC must also notify the recipient if the federal award is terminated for failure to comply with the federal statutes, regulations, or terms and conditions of the federal award. (45 CFR 75.373(b))
PAYMENT INFORMATION

The HHS Office of the Inspector General (OIG) maintains a toll-free number (1-800-HHS-TIPS [1-800-447-8477]) for receiving information concerning fraud, waste, or abuse under grants and cooperative agreements. Information also may be submitted by e-mail to hstips@oig.hhs.gov or by mail to Office of the Inspector General, Department of Health and Human Services, Attn: HOTLINE, 330 Independence Ave., SW, Washington DC 20201. Such reports are treated as sensitive material and submitters may decline to give their names if they choose to remain anonymous.

Payment Management System Subaccount: Funds awarded in support of approved activities have been obligated in a newly established subaccount in the PMS, herein identified as the “P Account”. Funds must be used in support of approved activities in the NOFO and the approved application. All award funds must be tracked and reported separately.

The grant document number identified on the bottom of Page 1 of the Notice of Award must be known in order to draw down funds.

CDC Staff Contacts

Grants Management Specialist: The GMS is the federal staff member responsible for the day-to-day management of grants and cooperative agreements. The GMS is the primary contact of recipients for business and administrative matters pertinent to grant awards.

GMS Contact:
Daryl Barksdale
Centers for Disease Control and Prevention
Chronic Disease and Birth Defects Services Branch
2920 Brandywine Road MS E-09
Atlanta, GA 30341
Email: xxj8@cdc.gov
Phone: 770-488-1087

Program/Project Officer: The PO is the federal official responsible for monitoring the programmatic, scientific, and/or technical aspects of grants and cooperative agreements, as well as contributing to the effort of the award under cooperative agreements.

POContact:
Deidra Green, Project Officer
Centers for Disease Control and Prevention
NCBDDD
Chamblee Building 101 Room 3112
Atlanta, Georgia 30341-3717
Telephone: 404-498-3034
Fax: 770-488-0270
Email: DGreen@cdc.gov

Grants Management Officer: The GMO is the federal official responsible for the business and other non-programmatic aspects of grant awards. The GMO is the only official authorized to obligate federal funds and is responsible for signing the NoA, including revisions to the NoA that change the terms and conditions. The GMO serves as the counterpart to the business officer of
the recipient organization.

GMOContact:  
Kathy Raible, GMO  
Centers for Disease Control and Prevention  
Chronic Disease and Birth Defects Services Branch  
2920 Brandywine Road Colgate MS E-09  
Atlanta, GA 30341  
Email:  kcr8@cdc.gov  
Phone:  770-488-2045
Missouri EHDI is making adequate progress in achieving all 5 strategies by the end of Year 1, but the ultimate challenge for MNHSP is around the Strategy 1. The ITSD is understaffed and frequently is required to focus efforts on projects with higher priorities than the MNHSP projects.

While MNHSP noted the ITSD challenge, there were several noted successes:

MNHSP is working with several departments to add individual maternal demographics to each MOHSAIC hearing screening case and create an electronic submission form for rescreening results MoEVR system.

The added data elements and the ability to collect non-Part C early intervention status in MOHSAIC, is in testing.

The BVS provided the approval required to add maternal demographics to the hearing screening application.

MNHSP will join in the talks with ManTech International Corporation for the enhancements to MoEVR.

The audiologist consultant compiled and distributed Benchmark Reports, which contain individualized data and information about proper reporting processes and requirements.

MNHSP shared the evaluation plan with the EHDI QI work group to spur development of pertinent quality improvement (QI) projects and enact other improvements to the program as indicated.
Technical Reviewer Evaluation Report
Annual Performance Report (APR) 2018 CDC-RFA-DD17-1701-02

Documentation and Use of Follow-up Diagnostic and Intervention Services Data through the Maintenance and Enhancement of the Early Hearing Detection and Intervention System (EHDI-IS).

Section 2: Year 2 Work Plan

Year 2 work plan is consistent with the funding purpose and scope and the proposed activities support the intent of the original NOFO. Based on the ESSET, MNHSP will continue to focus on 12 of the 55 EHDI-IS Functional Standards that MOHSAIC does not meet to improve the current EHDI-IS ability to collect complete and accurate follow-up diagnostic and intervention data. It is noted in Year 2 work plan the ongoing understaffed challenge within ITSD.

Strategy 1: Sub-strategy 1.3 and 1.4 should include measurable baselines.

Strategy 5: Sub-strategy 5.3 has no activities related to the submission of Year 1 Evaluation Report. Evaluation report is due September 30, 2018. Also, while there are activities related to Year 2 evaluation activities, Year 2 Evaluation Report is not due until September 30, 2019.

Outcomes
It appears as if a few sub-strategies 2015 Baselines and Targets slightly changed from Year 1, but no explanation.

Section 3: Year 3 Work Plan

Sub-strategy 5.3 has no activities related to analyzing evaluation report results; finalizing report or the submission of Year 2 evaluation report. The focus of the report is to assess the Quality of the Data and due September 30, 2019.

Outcomes
It appears as if a few sub-strategies 2015 Baselines and Targets slightly changed from Year 1, but no explanation.

Section 4: Estimated unobligated funds balance

MNHSP does not anticipate any unobligated funds at the end of Year 1.

Section 5: Budget Year 2

While the budget and all the required elements are included and the requested budget is reasonable for all the planned activities, the budget narrative does not identify all the key roles for the project.
Documentation and Use of Follow-up Diagnostic and Intervention Services Data through the Maintenance and Enhancement of the Early Hearing Detection and Intervention System (EHDI-IS).

**Section 6: Summary of recommendations for the work plan, and budget**

Budget narrative, provide all key roles for those serving in the Project Director, Project Manager, Surveillance and Evaluation roles, as applicable to include In-Kind. Reference original NOFO, if needed.

Sub-strategy 1.3 and 1.4 should include measurable baselines.

**Strategy 2:** If applicable, include number of meetings/trainings or delete template language “Number and Description of meeting”

**Strategy 3:** If applicable, include number of meetings or delete template language “Number and Description of meeting”

**Strategy 5:** Include an activity related to the submission of Years 1 and 2 Evaluation Report.

**Outcomes for Years 2 and 3,** all data should reflect the 2015 Baselines and Targets submitted in Year 1. Please use the work plan formulas.

**Year 3** work plan; Sub-strategy 5.3 should include activities related to analyzing, finalizing and submitting evaluation report. Due date September 30, 2019.

Delete activities related to creating evaluation plan and report in Year 3.